- Home
- PHAR vs ETWO Comparison
PHAR vs ETWO Comparison
Compare PHAR & ETWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- ETWO
- Stock Information
- Founded
- PHAR 1988
- ETWO 2000
- Country
- PHAR Netherlands
- ETWO United States
- Employees
- PHAR N/A
- ETWO N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- ETWO EDP Services
- Sector
- PHAR Health Care
- ETWO Technology
- Exchange
- PHAR Nasdaq
- ETWO Nasdaq
- Market Cap
- PHAR 731.1M
- ETWO 663.4M
- IPO Year
- PHAR N/A
- ETWO N/A
- Fundamental
- Price
- PHAR $10.00
- ETWO $3.26
- Analyst Decision
- PHAR Strong Buy
- ETWO Sell
- Analyst Count
- PHAR 3
- ETWO 4
- Target Price
- PHAR $30.00
- ETWO $2.78
- AVG Volume (30 Days)
- PHAR 3.6K
- ETWO 3.2M
- Earning Date
- PHAR 07-31-2025
- ETWO 07-10-2025
- Dividend Yield
- PHAR N/A
- ETWO N/A
- EPS Growth
- PHAR N/A
- ETWO N/A
- EPS
- PHAR N/A
- ETWO N/A
- Revenue
- PHAR $320,708,000.00
- ETWO $609,135,000.00
- Revenue This Year
- PHAR $13.31
- ETWO $1.84
- Revenue Next Year
- PHAR $7.68
- ETWO $2.32
- P/E Ratio
- PHAR N/A
- ETWO N/A
- Revenue Growth
- PHAR 24.13
- ETWO N/A
- 52 Week Low
- PHAR $6.65
- ETWO $1.75
- 52 Week High
- PHAR $12.61
- ETWO $4.82
- Technical
- Relative Strength Index (RSI)
- PHAR 43.61
- ETWO 68.39
- Support Level
- PHAR $9.99
- ETWO $3.21
- Resistance Level
- PHAR $10.59
- ETWO $3.24
- Average True Range (ATR)
- PHAR 0.35
- ETWO 0.01
- MACD
- PHAR -0.14
- ETWO -0.02
- Stochastic Oscillator
- PHAR 7.45
- ETWO 87.50
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About ETWO E2open Parent Holdings Inc.Class A
E2open Parent Holdings Inc is an end-to-end and cloud-based supply chain management SaaS platform. The company's software combines networks, data, and applications to provide a deeply embedded, mission-critical platform that allows customers to optimize the supply chain across channel shaping, business planning, logistics, trade, manufacturing, and supply management. The Group has one reportable segment consisting of cloud-based, end-to-end SCM software. Geographically, the company operates in the Americas, Europe, and Asia Pacific, out of which the majority is from the Americas.